+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Liver Model Market - Global Forecast 2026-2032- Product Image
Human Liver Model Market - Global Forecast 2026-2032- Product Image
Sale

Human Liver Model Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904934
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Liver Model Market is projected to reach USD 1.78 Billion in 2026. It is expected to continue growing at a CAGR of 9.00%, reaching USD 3.05 Billion by 2032.

The human liver model market is moving from a specialized research niche to a core enabler of drug discovery, toxicology, disease modeling, and precision medicine. Demand is being driven by the persistent challenge of drug-induced liver injury, the need for more predictive preclinical systems, and the rapid maturation of 3D liver spheroids, organoids, precision-cut liver slices, primary human hepatocytes, induced pluripotent stem cell-derived hepatocyte-like cells, and liver-on-chip platforms.

Human liver models are increasingly valued because the liver is central to drug metabolism, bile acid regulation, glucose and lipid homeostasis, and systemic detoxification. Conventional animal studies remain important in many regulatory pathways, but species differences in metabolism and immune response have reinforced the need for human-relevant in vitro systems. The FDA Modernization Act 2.0, European 3Rs policies, OECD work on non-animal methods, and expanding investment in microphysiological systems are strengthening the commercial case for validated human liver models across pharmaceutical, biotechnology, cosmetics, chemical, and academic research settings.

Transformative Shifts Reshaping Human Liver Models

The landscape is being reshaped by a shift from flat monolayer cultures toward complex, functionally stable human liver systems that better preserve hepatocyte phenotype, metabolic competence, and multicellular interactions. Researchers are prioritizing models that incorporate hepatocytes, Kupffer cells, stellate cells, sinusoidal endothelial cells, cholangiocytes, and extracellular matrix signals to reproduce inflammation, fibrosis, steatosis, cholestasis, and viral liver disease mechanisms with greater biological relevance.

Regulatory modernization is also accelerating change. The removal of the statutory requirement for animal testing in U.S. drug approvals under the FDA Modernization Act 2.0 did not eliminate the need for evidence, but it created a clearer pathway for qualified alternatives when supported by robust validation. In Europe, Directive 2010/63/EU and the work of EURL ECVAM continue to institutionalize replacement, reduction, and refinement principles. These developments are pushing vendors to demonstrate reproducibility, assay transferability, GLP readiness, and correlation with known human clinical outcomes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical force multiplier for human liver model development. AI-enabled image analysis is improving high-content screening of hepatotoxicity, mitochondrial stress, steatosis, fibrosis markers, and cell viability. Machine learning models are also being used to connect transcriptomic, proteomic, metabolomic, and phenotypic readouts to drug metabolism and toxicity signals, helping researchers identify patterns that may be missed through single-endpoint assays.

The most valuable AI applications are emerging where algorithms are paired with standardized, high-quality biological data. In liver-on-chip and organoid workflows, AI can support experimental design, anomaly detection, dose-response modeling, and predictive toxicology. However, adoption depends on explainability, data provenance, bias control, and alignment with good machine learning practices. Industry leaders that combine validated wet-lab models with transparent computational pipelines are best positioned to convert AI from an efficiency tool into a regulatory-grade decision support capability.

Regional Outlook for Human Liver Model Adoption

Asia-Pacific is expanding as China, Japan, South Korea, India, Singapore, and Australia invest in biomedical research infrastructure, organoid science, cell therapy, and pharmaceutical innovation. The region benefits from large patient populations, strong academic networks, and growing demand for liver disease research, including metabolic dysfunction-associated steatotic liver disease, viral hepatitis, and hepatocellular carcinoma. High hepatitis B burden in parts of Asia, increasing metabolic disease prevalence, and national programs supporting regenerative medicine and biotechnology are strengthening demand for human-relevant liver models in drug discovery and translational research.

North America remains a leading hub for human liver model commercialization, supported by the U.S. FDA, NIH-funded translational research, a deep biotechnology ecosystem, and strong demand from pharmaceutical sponsors for ADME, DMPK, and hepatotoxicity testing. Europe is distinguished by its mature 3Rs policy framework, EMA scientific engagement, EURL ECVAM activity, and a strong base of organ-on-chip and in vitro diagnostics innovators. Latin America, led by Brazil and Mexico, is gaining relevance through clinical research capacity, academic toxicology programs, and rising investment in life sciences. The Middle East is building momentum through precision medicine initiatives, genomics programs, and hospital-linked research in the GCC, while Africa presents long-term opportunity tied to infectious disease research, liver cancer burden, hepatitis surveillance, and expanding clinical research infrastructure.

Strategic Group Insights Across Economic Alliances

ASEAN markets are becoming important for applied biomedical research, contract research services, and translational medicine, with Singapore serving as a high-value hub for organoid, microfluidics, and precision health initiatives. The GCC is prioritizing genomics, advanced diagnostics, and health system modernization, creating demand for human-relevant liver models that can support population-specific pharmacology and toxicology studies, particularly as regional health systems address diabetes, obesity, and liver disease risks.

The European Union continues to shape global adoption through regulatory science, Horizon Europe funding, chemical safety initiatives, and harmonized standards for alternative methods. BRICS countries offer scale, diverse disease populations, and expanding pharmaceutical manufacturing, making them important for cost-efficient model development and validation studies across drug metabolism, hepatotoxicity, and disease biology. G7 economies lead in research funding, regulatory capability, and advanced biomanufacturing, while NATO-aligned countries increasingly emphasize secure life science supply chains, biosecurity, and resilient access to critical research technologies, including cell-based assays, microphysiological systems, and AI-enabled laboratory infrastructure.

Country-Level Opportunities in Human Liver Models

The United States leads in commercialization, venture-backed biotechnology, FDA engagement, and translational toxicology programs, while Canada contributes through stem cell research, academic networks, and precision medicine initiatives. Mexico is strengthening its role in nearshore life sciences services, and Brazil remains Latin America’s largest opportunity because of its pharmaceutical base, clinical research capacity, and burden of chronic liver disease, including viral hepatitis, alcohol-associated liver disease, and metabolic liver disorders.

In Europe, the United Kingdom is a strong center for organoid research, toxicology innovation, and life science investment. Germany brings engineering depth, bioprocessing capability, and strong pharmaceutical demand, while France, Italy, and Spain contribute through academic hepatology, clinical research, and public-private biomedical programs. Russia retains scientific capacity in pharmacology and cell biology, though market access and collaboration patterns are shaped by geopolitical constraints, sanctions exposure, and supply chain limitations affecting advanced laboratory technologies.

China is scaling organoid, cell culture, and drug discovery infrastructure at speed, supported by substantial biotechnology policy attention and a large liver disease research need. India is expanding as a cost-competitive R&D and CRO destination with rising pharmaceutical innovation and academic hepatology capacity. Japan is strong in regenerative medicine and iPSC-derived models, South Korea is advancing biochips, microphysiological systems, and pharmaceutical innovation, and Australia offers high-quality clinical research, translational medicine, and liver disease expertise, including strengths in viral hepatitis, metabolic disease, and precision health studies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biological relevance, reproducibility, and regulatory alignment. The strongest competitive positions will come from platforms that demonstrate stable liver function, clinically relevant endpoints, and transparent performance against reference compounds associated with known hepatotoxicity, cholestasis, steatosis, fibrosis, and drug metabolism liabilities.

Organizations should build partnerships with pharmaceutical sponsors, academic medical centers, CROs, and regulatory science consortia to accelerate validation. Investments in standardized protocols, qualified cell sources, lot-to-lot quality control, data integrity, and AI governance will be essential. Vendors should also develop region-specific commercialization strategies, with premium offerings for G7 and EU markets, translational partnerships in Asia-Pacific, and scalable service models for emerging economies.

Research Methodology and Data Validation

The research approach combines structured secondary research, regulatory analysis, technology assessment, and expert interpretation. Sources include peer-reviewed scientific literature, FDA and EMA guidance, OECD and EURL ECVAM resources, NIH and WHO data, clinical trial registries, patent landscapes, public disclosures, and publicly available funding and policy documents.

Insights are triangulated across product maturity, application areas, end-user adoption, regulatory relevance, and regional life science infrastructure. Emphasis is placed on verified evidence rather than unsupported market claims. Technologies are assessed on biological fidelity, assay robustness, scalability, workflow compatibility, data quality, and readiness for drug discovery, safety testing, disease modeling, and personalized medicine applications.

Conclusion: Strategic Imperatives for Growth

Human liver models are becoming foundational tools for safer drug development, more predictive toxicology, and deeper understanding of liver disease biology. Long-term adoption will depend on the convergence of validated biology, regulatory confidence, automation, AI-enabled analytics, and globally distributed research capacity.

Organizations that move beyond isolated assays toward integrated, data-rich, human-relevant liver platforms will be better positioned to reduce late-stage failures, support ethical research practices, and accelerate therapeutic innovation. The next phase of competition will be defined by evidence quality, interoperability, and the ability to translate complex liver biology into actionable decisions for drug developers and healthcare innovators.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Liver Model Market, by Offering
7.1. Introduction
7.2. Consumable Human Liver Models
7.3. Enabling Biological Inputs
7.4. Media, Matrix, & Assay Reagents
7.5. Platforms & Instrumentation
7.5.1. Static 3D Culture Plates
7.5.2. Hanging-Drop & Low-Attachment Platforms
7.5.3. Microfluidic Chip Platforms
7.5.4. Perfusion Controllers & Pumps
7.5.5. Bioprinting Platforms
7.6. Services
7.6.1. Fee-For-Service Toxicology Screening
7.6.2. Custom Liver Model Development
7.6.3. Disease Model Generation
8. Human Liver Model Market, by Model Type
8.1. Introduction
8.2. In Vitro Liver Models
8.2.1. 2D Liver Cell Culture Models
8.2.2. 3D Liver Spheroid Models
8.2.3. Liver Organoid Models
8.3. Ex Vivo Liver Models
8.3.1. Precision Cut Liver Slices
8.3.2. Perfused Liver Tissue Models
8.4. In Silico Liver Models
9. Human Liver Model Market, by Cell Source
9.1. Introduction
9.2. Immortalized Liver Cell Lines
9.3. Primary Human Hepatocytes
9.4. Stem Cell-Derived Models
9.5. Hepatic Cell Lines
10. Human Liver Model Market, by Material Type
10.1. Introduction
10.2. Natural
10.3. Synthetic
11. Human Liver Model Market, by Application
11.1. Introduction
11.2. Drug Metabolism & Pharmacokinetics Studies
11.3. Toxicology Testing
11.4. Disease Modeling
11.4.1. Liver Fibrosis Models
11.4.2. Non-Alcoholic Fatty Liver Disease Models
11.4.3. Hepatitis Models
11.4.4. Liver Cancer Models
11.5. Regenerative Medicine & Tissue Engineering
11.6. Personalized Medicine
12. Human Liver Model Market, by End Users
12.1. Introduction
12.2. Biotech Companies
12.3. Contract Research Organizations
12.4. Pharmaceutical Companies
12.5. Research Laboratories
13. Human Liver Model Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Human Liver Model Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Human Liver Model Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. 3-D Matrix, Ltd.
17.2. AIM Biotech Pte. Ltd.
17.3. AnaBios Corporation
17.4. Ascendance Bio
17.5. Beonchip S.L.
17.6. BioIVT LLC
17.7. BiomimX S.r.l.
17.8. Biopredic International
17.9. Cellink Global by BICO Group AB
17.10. Cherry Biotech SAS
17.11. CN Bio Innovations Ltd.
17.12. Corning Incorporated
17.13. Cyfuse Biomedical K.K.
17.14. Dynamic42 GmbH
17.15. EISCO Scientific LLC
17.16. Emulate Inc.
17.17. FluidForm Bio, Inc.
17.18. FUJIFILM Cellular Dynamics, Inc.
17.19. HemoShear Therapeutics, Inc.
17.20. Hesperos, Inc.
17.21. Hurel Corporation
17.22. InSphero AG
17.23. Kirkstall Ltd
17.24. Lonza Group AG
17.25. Merck KGaA
17.26. MIMETAS B.V.
17.27. NeurOmics, Inc.
17.28. Organovo Holdings Inc.
17.29. Pandorum Technologies Private Limited
17.30. PhoenixBio Co., Ltd.
17.31. React4life S.p.A.
17.32. REPROCELL Inc.
17.33. Sartorius AG
17.34. STEMCELL Technologies Inc.
17.35. Thermo Fisher Scientific Inc.
17.36. Tokyo Future Style, Inc.
17.37. VivoSim Labs, Inc.
List of Figures
FIGURE 1. GLOBAL HUMAN LIVER MODEL MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HUMAN LIVER MODEL MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HUMAN LIVER MODEL MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HUMAN LIVER MODEL MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HUMAN LIVER MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONSUMABLE HUMAN LIVER MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONSUMABLE HUMAN LIVER MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONSUMABLE HUMAN LIVER MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ENABLING BIOLOGICAL INPUTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ENABLING BIOLOGICAL INPUTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ENABLING BIOLOGICAL INPUTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MEDIA, MATRIX, & ASSAY REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MEDIA, MATRIX, & ASSAY REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MEDIA, MATRIX, & ASSAY REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PLATFORMS & INSTRUMENTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PLATFORMS & INSTRUMENTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PLATFORMS & INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL STATIC 3D CULTURE PLATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STATIC 3D CULTURE PLATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STATIC 3D CULTURE PLATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL HANGING-DROP & LOW-ATTACHMENT PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HANGING-DROP & LOW-ATTACHMENT PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HANGING-DROP & LOW-ATTACHMENT PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MICROFLUIDIC CHIP PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MICROFLUIDIC CHIP PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MICROFLUIDIC CHIP PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PERFUSION CONTROLLERS & PUMPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PERFUSION CONTROLLERS & PUMPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PERFUSION CONTROLLERS & PUMPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOPRINTING PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOPRINTING PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BIOPRINTING PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL FEE-FOR-SERVICE TOXICOLOGY SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FEE-FOR-SERVICE TOXICOLOGY SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL FEE-FOR-SERVICE TOXICOLOGY SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CUSTOM LIVER MODEL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CUSTOM LIVER MODEL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CUSTOM LIVER MODEL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DISEASE MODEL GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL DISEASE MODEL GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL DISEASE MODEL GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IN VITRO LIVER MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IN VITRO LIVER MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IN VITRO LIVER MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL 2D LIVER CELL CULTURE MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL 2D LIVER CELL CULTURE MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL 2D LIVER CELL CULTURE MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL 3D LIVER SPHEROID MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL 3D LIVER SPHEROID MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL 3D LIVER SPHEROID MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LIVER ORGANOID MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LIVER ORGANOID MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LIVER ORGANOID MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL EX VIVO LIVER MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL EX VIVO LIVER MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL EX VIVO LIVER MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PRECISION CUT LIVER SLICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PRECISION CUT LIVER SLICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PRECISION CUT LIVER SLICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PERFUSED LIVER TISSUE MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PERFUSED LIVER TISSUE MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PERFUSED LIVER TISSUE MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL IN SILICO LIVER MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL IN SILICO LIVER MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IN SILICO LIVER MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL IMMORTALIZED LIVER CELL LINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL IMMORTALIZED LIVER CELL LINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL IMMORTALIZED LIVER CELL LINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PRIMARY HUMAN HEPATOCYTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PRIMARY HUMAN HEPATOCYTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PRIMARY HUMAN HEPATOCYTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL STEM CELL-DERIVED MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL STEM CELL-DERIVED MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL STEM CELL-DERIVED MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HEPATIC CELL LINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HEPATIC CELL LINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HEPATIC CELL LINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL NATURAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL DRUG METABOLISM & PHARMACOKINETICS STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL DRUG METABOLISM & PHARMACOKINETICS STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL DRUG METABOLISM & PHARMACOKINETICS STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL DISEASE MODELING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL DISEASE MODELING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL DISEASE MODELING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL LIVER FIBROSIS MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL LIVER FIBROSIS MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL LIVER FIBROSIS MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HEPATITIS MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HEPATITIS MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HEPATITIS MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL LIVER CANCER MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL LIVER CANCER MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LIVER CANCER MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL REGENERATIVE MEDICINE & TISSUE ENGINEERING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL REGENERATIVE MEDICINE & TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL REGENERATIVE MEDICINE & TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 166. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 168. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 169. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 170. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 171. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 172. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 173. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 174. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 175. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 176. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 177. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 190. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 194. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 195. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 196. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 197. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 198. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 199. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 201. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 205. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 206. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 207. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 208. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 209. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 210. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 211. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 212. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 213. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 214. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 215. GCC HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. GCC HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 217. GCC HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 218. GCC HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 219. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 220. GCC HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 221. GCC HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 222. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 223. GCC HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 224. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. GCC HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 226. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 239. BRICS HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. BRICS HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 241. BRICS HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 242. BRICS HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 243. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 244. BRICS HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 245. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 246. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 247. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 248. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. BRICS HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 250. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 251. G7 HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 252. G7 HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 253. G7 HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 254. G7 HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 255. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 256. G7 HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 257. G7 HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 258. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 259. G7 HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 260. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 261. G7 HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 262. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 263. NATO HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. NATO HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 265. NATO HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 266. NATO HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 267. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 268. NATO HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 269. NATO HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 270. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 271. NATO HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 272. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. NATO HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 274. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 275. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 288. CANADA HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CANADA HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 290. CANADA HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 291. CANADA HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 292. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 293. CANADA HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 294. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 295. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 296. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 297. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 298. CANADA HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 299. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 300. MEXICO HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 302. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 303. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 304. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 305. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 306. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 307. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 308. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 309. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 310. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 311. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 323. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 336. GERMANY HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 338. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 339. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 340. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 341. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 342. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 343. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 344. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 345. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 346. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY DISEASE MODELING, 2017-2032 (USD MILLION)
TABLE 347. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 348. FRANCE HUMAN LIVER MODEL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 350. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY PLATFORMS & INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 351. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 352. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 353. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY IN VITRO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 354. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO LIVER MODELS, 2017-2032 (USD MILLION)
TABLE 355. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 356. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 357. FRANCE HUMAN LIVER MODEL MARKE

Companies Mentioned

  • 3-D Matrix, Ltd.
  • AIM Biotech Pte. Ltd.
  • AnaBios Corporation
  • Ascendance Bio
  • Beonchip S.L.
  • BioIVT LLC
  • BiomimX S.r.l.
  • Biopredic International
  • Cellink Global by BICO Group AB
  • Cherry Biotech SAS
  • CN Bio Innovations Ltd.
  • Corning Incorporated
  • Cyfuse Biomedical K.K.
  • Dynamic42 GmbH
  • EISCO Scientific LLC
  • Emulate Inc.
  • FluidForm Bio, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • HemoShear Therapeutics, Inc.
  • Hesperos, Inc.
  • Hurel Corporation
  • InSphero AG
  • Kirkstall Ltd
  • Lonza Group AG
  • Merck KGaA
  • MIMETAS B.V.
  • NeurOmics, Inc.
  • Organovo Holdings Inc.
  • Pandorum Technologies Private Limited
  • PhoenixBio Co., Ltd.
  • React4life S.p.A.
  • REPROCELL Inc.
  • Sartorius AG
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Tokyo Future Style, Inc.
  • VivoSim Labs, Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.05 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned37

Related Topics

Related Reports

Human Liver Models - Global Strategic Business Report - Product Image

Human Liver Models - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Human Organs-on-Chips Market - Global Forecast 2026-2032 - Product Image

Human Organs-on-Chips Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Organs-on-chips Market - Global Forecast 2026-2032 - Product Image

Organs-on-chips Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Human Liver Model Market: 2026 Edition - Product Image

Human Liver Model Market: 2026 Edition

  • Report
  • 148 Pages
  • Global
From
Human Liver Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Human Liver Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 192 Pages
  • Global
From

About the Human Liver Model Market

The Human Liver Model market is a subset of the Clinical Trials market, focused on the development of in vitro models of the human liver. These models are used to study the effects of drugs and other compounds on the liver, and to predict the safety and efficacy of drugs in humans. The models are typically composed of human liver cells, and can be used to study the metabolism, toxicity, and pharmacokinetics of drugs. The models are also used to study the effects of genetic and environmental factors on the liver. The Human Liver Model market is growing due to the increasing demand for in vitro models for drug development and safety testing. The models are also being used to study the effects of diseases on the liver, such as hepatitis and cirrhosis. Companies in the Human Liver Model market include InSphero, Hepregen, and Emulate. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.